Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the ...

“For more than three decades, people with chronic kidney disease and type 1 diabetes have had limited options to address the risk of kidney disease progression,"2 said Dr. Janet McGill, Professor of ...

Updated consumer resource explains eGFR and UACR testing, individualized nutrition, medication oversight and how to ...

Heart disease and chronic kidney disease can accelerate one another, but new guidelines say simple screening and early treatment could substantially reduce the risks. Blood and urine tests, combined ...

The first-ever European Society of Cardiology Guidelines on the management of cardiovascular disease and chronic kidney disease have been developed in collaboration with the European Renal Association ...

Some of the most pressing health conditions — including heart disease, kidney disease and diabetes — are best managed as a whole, according to a new clinical guideline. Published June 9 in Circulation ...

A new research project launched by Kidney Wales and Aston University will explore how living with chronic kidney disease affects people's financial wellbeing. Chronic kidney disease (CKD) is a ...

The FDA approved KERENDIA to reduce UACR, which is expected to slow chronic kidney disease progression in adults with CKD associated with T1D.1 This approval is important for patients, as it is the ...